Scholarlink

Background <p>Colorectal cancer (CRC) is a leading malignant tumor worldwide with rising morbidity and mortality. Cathepsin E (CTSE), a member of the cysteinyl asparaginase family, is implicated in immune responses, antigen processing, and cellular signaling.</p> Methods <p>The biological functions of CTSE in CRC were assessed through in vitro and in vivo experiments evaluating proliferation, invasion, and metastasis. Mechanistic studies utilized knockdown approaches, pathway inhibition, and analysis of post-translational modifications to investigate CTSE-mediated ADP-ribosylation. The impact of CTSE on tumor immunity was examined by analyzing PD-L1/PD-1 interactions and CD8<sup>+</sup> T cell-mediated cytotoxicity.</p> Results <p>CTSE promoted CRC proliferation, invasion, metastasis, and immune escape. Mechanistically, CTSE stabilized ZNF326 by promoting its ADP-ribosylation at glutamate 338, thereby activating TGF-β/SMAD pathway. The tumor-promoting effect was abolished by ZNF326 knockdown or TGF-β/SMAD pathway inhibition. Furthermore, CTSE enhanced PD-L1/PD-1 interactions and reduced secretion of anti-tumor factors, thereby impairing CD8<sup>+</sup> T cell recognition and killing of tumor cells.</p> Conclusions <p>CTSE drives CRC progression by stabilizing ZNF326 via ADP-ribosylation and activating TGF-β/SMAD pathway, while facilitating tumor immune evasion. CTSE represents a promising therapeutic target for CRC, and its combination with PD-1/PD-L1 inhibitors may synergistically enhance anti-tumor efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cathepsin E drives colorectal cancer progression and immune evasion via ZNF326 ADP-ribosylation and TGF-β/SMAD activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月14日

查看全文
  • Huan Zhang,
  • Jie Feng,
  • Mengxin Zhu,
  • Tongguo Shi,
  • Qinhua Xi

摘要

Background

Colorectal cancer (CRC) is a leading malignant tumor worldwide with rising morbidity and mortality. Cathepsin E (CTSE), a member of the cysteinyl asparaginase family, is implicated in immune responses, antigen processing, and cellular signaling.

Methods

The biological functions of CTSE in CRC were assessed through in vitro and in vivo experiments evaluating proliferation, invasion, and metastasis. Mechanistic studies utilized knockdown approaches, pathway inhibition, and analysis of post-translational modifications to investigate CTSE-mediated ADP-ribosylation. The impact of CTSE on tumor immunity was examined by analyzing PD-L1/PD-1 interactions and CD8+ T cell-mediated cytotoxicity.

Results

CTSE promoted CRC proliferation, invasion, metastasis, and immune escape. Mechanistically, CTSE stabilized ZNF326 by promoting its ADP-ribosylation at glutamate 338, thereby activating TGF-β/SMAD pathway. The tumor-promoting effect was abolished by ZNF326 knockdown or TGF-β/SMAD pathway inhibition. Furthermore, CTSE enhanced PD-L1/PD-1 interactions and reduced secretion of anti-tumor factors, thereby impairing CD8+ T cell recognition and killing of tumor cells.

Conclusions

CTSE drives CRC progression by stabilizing ZNF326 via ADP-ribosylation and activating TGF-β/SMAD pathway, while facilitating tumor immune evasion. CTSE represents a promising therapeutic target for CRC, and its combination with PD-1/PD-L1 inhibitors may synergistically enhance anti-tumor efficacy.